IXCIO delivers strong H1 2025 results, reporting 26% year-on-year revenue growth to £3.2 million, driven by increased demand for its AI-powered neurological clinical trial analytics platform, TrialTracker. With a 10-point improvement in gross margin (rising to 50%) and a halved EBITDA loss of £700k, the company demonstrates significant operational leverage. The expanded order book, now at £13.1 million, offers full coverage of FY25 revenue guidance, supported by long-term contracts across 25 projects and 17 clients. Strategic investments post-capital raise are focused on platform innovation, commercial scaling, and expanding into high-growth neurodegenerative markets such as Alzheimer’s and Parkinson’s—boosting ISIO’s addressable market by up to 4x. Notably, new imaging biomarkers are being deployed to unlock multimodal revenue opportunities beyond the CRO model. Backed by a £5 million cash reserve and a debt-free balance sheet, ISIO is well-positioned for sustained growth, with a clear path to platform monetisation, broader market penetration, and potential partnerships across biopharma and diagnostics. This investor update highlights ISIO’s compelling investment case, underscored by technology leadership, diversified revenue streams, and a growing footprint in the US.

Grainger plc (LSE:GRI), the UK’s largest listed residential landlord, reported robust half-year financial results, underpinned by strong operational performance and accelerated growth in its purpose-built build-to-rent (BTR) portfolio. Net rental income rose 15%, earnings increased 23%, and the dividend advanced 12%, reflecting resilient demand, efficient cost control, and strategic asset recycling. With over 11,000 homes in operation and a committed pipeline of 5,000 fully funded units, Grainger forecasts 50% earnings growth by FY29 and 25% by FY26. Occupancy remains high at 96%, gross-to-net margins have improved to 25%, and customer retention stands at a healthy 62%, supported by a scalable operating platform and technology-driven efficiencies. The company benefits from inflation-linked rental growth and is well-positioned within a structurally undersupplied rental market. Grainger is progressing toward REIT conversion by FY26, with minimal refinancing needs until 2029, over £200m in annual cash flow, and significant optionality from £1.1bn in low-yielding non-core asset sales. Management highlights long-term value creation through disciplined capital recycling, margin expansion, and sustainable 8%+ total accounting returns—with current share price metrics implying an 11% return. Backed by strong fundamentals, low volatility, and a favourable regulatory outlook, Grainger offers investors compelling exposure to the UK’s high-growth BTR sector.

Nexus Infrastructure plc has reported a strong set of interim results for the period ending 31 March 2025, highlighting clear momentum across all key metrics. Group revenue rose to £30.6m, driven by an 8% increase in housebuilding activity via Tamdown (£27.8m) and a £2.8m contribution from newly acquired Coleman, operating in the water and rail sectors. Gross profit surged 31% to £4.6m, with group gross margins improving to 14.9%—boosted by Coleman’s 28% margin. The order book climbed to over £95m by May, reflecting solid demand and successful execution of Nexus’ diversification strategy. The integration of Coleman is progressing well, providing exposure to the AMP8 water investment cycle, with £104bn sector-wide spend planned nationally. In housing, early signs of recovery are evident, supported by government planning reforms and increased developer activity. Tamdown remains well-positioned for long-term, multi-phase infrastructure contracts across the Southeast, while Coleman expands opportunities through critical water projects for clients like Southern Water. Cash reserves rose to £9.6m, despite acquisition costs, supporting future growth and capital investment. The company declared an interim dividend of 1p per share, reaffirming its commitment to shareholder returns. With improved financial performance, a growing order pipeline, and robust market fundamentals in both housing and utilities, Nexus Infrastructure is confidently executing its growth strategy for FY2025 and beyond.

Creo Medical Group Plc (AIM: CREO), delivered a pivotal year of strategic transformation, marked by robust core revenue growth, operational efficiencies, and accelerating commercial traction. Core product revenue rose 74% to £4 million in 2024, driven by expanded adoption of its Speedboat and Chroma platforms, alongside new product launches including SpydrBlade, MicroBlate Flex, and Fine. With over 38 clinical investigators across 14 global studies, Creo has significantly scaled its clinical evidence base to support wider adoption and reimbursement. The company strengthened its balance sheet with a successful strategic transaction with Micro-Tech, enhancing cash reserves and establishing a high-margin joint venture with long-term revenue visibility. Operational streamlining is delivering £5 million in annualised cost savings, with additional efficiencies to follow as Creo moves toward an outsourced manufacturing model and improved EBITDA margins. Gross margin improved from 40% to 45%, with targets of over 60% in the medium term. Guidance for 2025 anticipates core revenue growth of 40–60%, supported by deeper product utilisation, geographic expansion, and a shift to quality recurring revenue. The outlook excludes speculative Comaptiv licensing deals, reflecting a prudent, execution-led strategy. With regulatory milestones largely complete, including CE and MDR clearances, Creo is well-positioned for commercial scalability and cashflow break-even by 2026. Investors can expect continued growth from the US, UK, and China, driven by strong partnerships, new product rollouts, and rising procedural demand in therapeutic endoscopy.

Angling Direct (AIM: ANG) has delivered record FY25 financial results, underscoring its strategic momentum and positioning as the UK’s leading specialist fishing tackle retailer. Group revenue rose 11.9% to £86.4 million, driven by 11.7% UK sales growth and 14.1% European growth. EBITDA increased 20%, supported by a 140bps gross margin expansion in the UK. The company continues to advance towards its medium-term objectives, including £100 million UK revenue and >6% adjusted EBITDA margin by FY28. Core growth drivers include its proprietary MyAD loyalty platform—now with over 400,000 members—targeted data-led marketing, store network expansion, and enhanced digital capability. Investments in automation, own-brand logistics, and omnichannel retail tech are yielding efficiency gains and higher customer engagement. European operations remain focused on the Netherlands and Germany, with a break-even target by FY28. Cash reserves stand at £12 million, with disciplined deployment across store rollouts, automation, M&A, and a £4 million share buyback. FY26 is off to a strong start, with Q1 sales up 17% YoY. Angling Direct’s performance reflects resilience amid cost headwinds and its clear execution roadmap for sustained profitable growth across the UK and Europe.

Ondine Biomedical Inc. (LSE: OBI) delivered a transformative year in 2024, marked by strong commercial expansion, strategic partnerships, and accelerating clinical progress. Full-year revenue increased by over 70% to C$2 million, driven by an 81% rise in hospital deployments and enhanced same-site sales growth. Gross margin improved by 600 basis points to 64%, supported by operational efficiencies and the launch of the high-volume Steriwave nasal illuminator system. The company secured C$21.7 million in new funding, including a strategic post-period investment from HCA Healthcare, bringing year-end cash reserves to nearly C$10 million. Clinical milestones included the commencement of a pivotal U.S. Phase 3 study with HCA and the launch of a major ICU trial in Canada. Ondine's flagship Steriwave technology—based on proprietary photodisinfection—targets healthcare-associated infections (HAIs) and is now adopted by five of the top ten Canadian hospitals and five NHS trusts in the UK. Supported by a global distribution partnership with Mölnlycke Healthcare, Ondine is poised for international expansion across the EU, Middle East, and Mexico. With rising adoption, recurring consumable revenues, and proven real-world outcomes, Ondine continues to strengthen its growth strategy, targeting multibillion-dollar addressable markets in pre-surgical and ICU infection prevention. Backed by strong shareholder alignment, cost discipline, and a robust pipeline, the company is well-positioned to achieve operational scale and regulatory progress in 2025 and beyond.

Vertu Motors plc, the UK’s only major listed franchised motor retailer, delivered a resilient FY2024 performance against a backdrop of significant automotive sector disruption. Despite a decline in headline profits driven by the UK government's Zero Emission Vehicle (ZEV) mandate and subdued new retail car volumes, the Group achieved revenue growth via acquisitions and improved gross margins through a strong mix of high-margin aftersales services. Core aftersales gross profit rose £12.3 million like-for-like, underpinned by robust customer retention, a growing service plan base, and smart digital tools like its proprietary Pay Later scheme. Used vehicle profits also rose £5.7 million year-on-year, supported by disciplined stock management and pricing technology. Vertu continues to leverage its scale and digital capabilities—such as daily AI-driven pricing updates and automated back-office processes—while executing a streamlined single-brand strategy expected to generate £5 million in medium-term savings. With tangible net assets per share at 72.9p and a significant ongoing share buyback programme, the Group remains committed to shareholder returns and prudent capital allocation. Looking ahead, Vertu anticipates margin recovery as interest rates ease, used car supply remains constrained, and the new retail market shows signs of revival. Management remains focused on portfolio optimisation, digital transformation, and disciplined growth, including selective expansion into high-performing Chinese EV brands like BYD. With a well-capitalised balance sheet, experienced leadership, and a culture of agile execution, Vertu is well positioned to navigate ongoing industry evolution and drive long-term value for shareholders.

Specialty chemical company IOFINA (Iofina plc) delivered a strong FY2024 performance with record revenues of $54.5 million, up 9% year-on-year, and a 13% increase in iodine production to 634 metric tonnes—solidifying its position as the second-largest iodine producer in North America. With vertically integrated operations spanning iodine extraction (Iofina Resources) and specialty chemical manufacturing (Iofina Chemical), the company continues to execute its growth strategy through efficient capital deployment, technological innovation, and geographic expansion. The construction of IO#11 and plans for IO#12 demonstrate commitment to doubling iodine output while diversifying revenue streams via value-added iodine derivatives, which grew 31% year-on-year. Operating profit reached $5 million, supported by a strong net cash position of $2.9 million and enhanced credit facilities to fund future growth. IFINA’s proprietary ISO extraction technology leverages waste brine from oil and gas operations, positioning the company as a cost-effective and environmentally conscious supplier in a niche market experiencing robust global demand. With iodine prices exceeding $70/kg and no major new supply expected in 2025, the company is well-placed to benefit from tight market dynamics. Management reaffirmed its ambition to become North America’s leading iodine producer, while maintaining disciplined capital allocation, continued product innovation, and a focus on long-term shareholder value.

Central Asia Metals PLC (AIM: CAML) presented a strong operational and financial performance at its 2025 AGM and investor update, reinforcing its commitment to shareholder returns and future growth. For the year ended 31 December 2024, the company reported revenue of $215 million, an EBITDA of $101.8 million with a 47% margin, and free cash flow of $65.7 million, supporting an 18p dividend. Core assets, Kounrad (copper) and Sasa (lead and zinc), delivered resilient production and margin performance, with key infrastructure upgrades enhancing operational efficiency. CAML remains debt-free, holding $67.6 million in cash, and continues to prioritize disciplined capital allocation, shareholder dividends, and accretive growth opportunities, particularly in base metals across the European time zone and Kazakhstan. Strategic investments in sustainability, dry stack tailings, and emissions reduction further underpin its long-term operational resilience. With an active M&A pipeline, strong balance sheet, and a clear growth strategy, Central Asia Metals is well positioned to deliver value amid increasing demand for copper, lead, and zinc critical to the global energy transition.

Conduit Holdings Limited delivered a strong Q1 2025 trading update, reporting 15% growth in underwriting premiums to $410.2 million and a 2.1% investment return, driven by disciplined capital management and strategic portfolio diversification. The company maintained its mid-teen ROE targets despite rate softening, supported by resilient growth across property, casualty, and specialty lines. Following leadership transitions, Conduit strengthened its capital strategy with a newly announced $50 million share buyback program, aiming to enhance shareholder value and capital efficiency. Secondary peril reinsurance coverage was expanded to reduce earnings volatility after the Los Angeles wildfire event. With a focus on sustainable margins, prudent underwriting, a strong order book, and ongoing growth strategy execution, Conduit remains well-positioned to navigate market cycles and deliver long-term financial results.